此外,纳米酶产生的活性氧(reactive oxygen species, ROS)可触发肿瘤细胞的免疫原性细胞死亡(immunogenic cell death, ICD),增强树突状细胞(dendritic cells, DC)的募集,激活肿瘤免疫然而,低温肿瘤中免疫抑制TME的存在阻碍了纳米酶为基础的肿瘤催化治疗的系统抗肿瘤效果,该肿瘤具有免疫原性低、T细胞浸润不足等特点。 光热...
Organellar and cellular stress are induced during immunogenic cell death (ICD), a particularly functional response pattern. ICD is a separate but poorly characterized entity caused by various cancer treatments. The induction of ICD has the potential to change TME and the recruitment of tumor-...
结果表明,配位/氧化还原双响应的MONs能够有效放大ICD以增强对肿瘤的化学-免疫治疗效果。 Fan Zhang. et al. Coordination and Redox Dual-Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy. Small. 2021 DOI: 10.1002/smll.202100006 https://onlinelibrary.wil...
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine (NE) cancer that accounts for ~15% of all lung cancer, with an annual incidence of more than 34,000 in the United States alone. Treatment of SCLC has historically consisted of chemotherapy with platinum and etoposide, which ...
Table 1. Characteristics of the Full Sample of Patients With Advanced Non–Small Cell Lung Cancer (N = 5688) View LargeDownload Table 2. Survival Results for Instrumental Variable and Propensity Score Matched Analysesa View LargeDownload Table 3. Treatments Received by Patients With Advanced...
The efficacy of checkpoint inhibitor (CPI) immunotherapy in patients with non–small cell lung cancer (NSCLC) is limited by a lack of strongly predictive response markers, subjecting patients to potential underutilization of alternative effective treatments, increased risk for futile care, and unnecessar...
Patients were excluded if they had a history of chemotherapy used primarily in small cell lung cancer, or a medical claim associated with an unrelated malignancy. The timing of molecular testing was compared with the start of chemotherapy and targeted therapy, if applicable. Results...
The standard treatment of stage III N2 small cell lung cancer (SCLC) is concurrent chemoradiation, and surgery is not recommended. This study was aimed to evaluate whether surgery has survival benefits in patients with stage III N2 SCLC and investigate the factors influencing survival of surgery. ...
Figure 4. Distribution of Initial Treatment by NSCLC Stage (SEER-18, 2016) View LargeDownload NSCLC indicates non–small cell lung cancer; SEER-18, Surveillance, Epidemiology, and End Results. A, for all ages; B, for those younger than 65 years; and C, those aged 65 years or older. Mu...
Table S2. Differentially Expressed Genes (DEGs) across Pseudotime and Cell-Type Signatures for Single-Cell Identification of Non-tumor Cell Populations; Cycling Signatures Used to Regress Out Effects due to Cell Proliferation, and Tumor Cell Barcodes Used for Tumor Cell-Specific Analyses from RPM Tra...